Glecirasib (JAB-21822) is a KRAS G12C inhibitor independently developed by Jacobio. From the in-house preclinical head-to-head study, this compound has superior oral bioavailability and systemic drug exposure, better pharmacokinetic profiles and tolerance, and is a potential best-in-class compound.

As date of Mar 19, 2025

• China
• Global

Glecirasib

Therapy	Indications	Phase I	Phase IIa	Phase IIb Pivotal	Phase III Pivotal	Recent progress	China Partner	Jacobio Rights
Mono	≥2L NSCLC					NDA accepted and granted Priority Review designation May 2024		Global rights outside of China
Mono	≥2L PDAC & Multi-tumor basket					BTD granted Aug 2023 Pivotal study FPI Oct 2023
Combo w/SHP2i JAB-3312	1L NSCLC					Registrational Phase III trial FPI Aug 2024
Combo w/EGFR mAb	≥3L CRC					Registrational Phase III trial approved May 2024
Mono	NSCLC、PDAC、CRC and other solid tumors

Sitneprotafib（JAB-3312） is the second SHP2 inhibitor approved by the FDA to enter clinical development. JAB-3312, the second generation SHP2 inhibitor designed by Jacobio has more potent anti-tumor activities. Both compounds have been granted orphan drug designation by the FDA for the treatment of esophageal cancer (including esophageal squamous cell carcinoma).

As date of Mar 19, 2025

• U.S.
• China
• Global

JAB-3312

Therapy	Indications	Phase I	Phase IIa	Phase III Pivotal	Recent progress	China Partner	Jacobio Rights
KRAS G12Ci Combination Therapy Glecirasib	1L KRAS G12C mut NSCLC				Registrational Phase III trial FPI Aug 2024		Global rights outside of China

 

 

Pan-KRAS inhibitor JAB-23E73 targets multiple KRAS mutants in both RAS(ON) and RAS (OFF), with good selectivity over HRAS and NRAS.

JAB-2485 is an Aurora Kinase A (AURKA) inhibitor developed independently by Jacobio Pharma. It inhibits AURKA effectively and does not affect the activity of other kinases structurally similar to AURKA, minimizing the toxicity of the drug and improving the therapeutic window.

JAB-BX300 is Jacobio’s self-developed LIF mAb. LIF is an important biomarker in pancreatic ductal adenocarcinoma (PDAC). Studies show that, LIF plays a crucial role in KRAS-driven cancer models and the blockade of LIF by antibodies represents an attractive approach to improving therapeutic outcomes. LIF is an attractive target for the treatment of KRAS-driven tumors, which has potential to combo with KRAS and SHP2 inhibitors.

JAB-BX600 is a small-molecule KRAS G12D inhibitor. Currently, there is only one small molecule KRAS G12D program in the Phase I clinical stage in respective drug classes globally. Therefore, JAB-BX600 has the potential to be among the first few market entrants.

JAB-8263 class 1 innovative drug that is a Bromodomain and Extra-Terminal motif (BET) inhibitor independently developed by Jacobio. Preclinical studies have n that JAB-8263 can effectively inhibit tumor growth at very low concentrations. In addition to solid tumors, hematological tumors are particularly sensitive to JAB-8263. Patients with hematological tumors and some types of solid tumors may benefit from the treatment of JAB-8263.

JAB-24114 is Jacobio’s self-developed GUE (glutamine-utilizing enzyme) inhibitor. Tumor growth is highly dependent on glutamine, which can be converted into various metabolites by multiple glutamine-utilizing enzymes (GUEs). These metabolites support a variety of tumor growth pathways. JAB-24114 can inhibit multiple GUEs, leading to simultaneous blockade of multiple glutamine metabolism pathways, with great therapeutic potential. Compared with its similar product, JAB-24114 has a wider therapeutic window. JAB-24114 has the distinctive combination effects of depleting tumors of nutrients while enhancing T cell function. Synergistic action with anti-PD-(L)1 can boost the anti-tumor effect. JAB-24114 can also be used in combination with SHP2 inhibitors or KRAS inhibitors.

JAB-2485 is an Aurora Kinase A (AURKA) inhibitor developed independently by Jacobio Pharma. It inhibits AURKA effectively and does not affect the activity of other kinases structurally similar to AURKA, minimizing the toxicity of the drug and improving the therapeutic window.

JAB-30355 is an orally bioavailable small molecule activator for the treatment of patients with locally advanced or metastatic solid tumors harboring P53 Y220C mutation. Studies shows that, JAB-30355 has shown very high binding affinity to P53 Y220C mutant proteins. Tumor regression was achieved in multiple cancer models covering various tumor types, such as gastric cancer, ovarian cancer, breast cancer and lung cancer. The synergistic effect was found when combined with chemo or oncogenic protein inhibitors which indicates a widely combo potential of JAB-30355.

JAB-24114 is Jacobio’s self-developed GUE (glutamine-utilizing enzyme) inhibitor. Tumor growth is highly dependent on glutamine, which can be converted into various metabolites by multiple glutamine-utilizing enzymes (GUEs). These metabolites support a variety of tumor growth pathways. JAB-24114 can inhibit multiple GUEs, leading to simultaneous blockade of multiple glutamine metabolism pathways, with great therapeutic potential. Compared with its similar product, JAB-24114 has a wider therapeutic window. JAB-24114 has the distinctive combination effects of depleting tumors of nutrients while enhancing T cell function. Synergistic action with anti-PD-(L)1 can boost the anti-tumor effect. JAB-24114 can also be used in combination with SHP2 inhibitors or KRAS inhibitors.